Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Myeloproliferative Neoplasms
Ruxolitinib Plus PEG-IFNα2 for Patients With Polycythemia Vera or Myelofibrosis
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
Increased Risk for Hemorrhage With Aspirin Plus Anticoagulation for Polycythemia Vera
Patients receiving aspirin and anticoagulation experienced a 3-fold increase in risk for severe hemorrhage compared with patients receiving either treatment alone.
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms
Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.
Low Erythropoietin Levels May Have Limited Diagnostic Value for Polycythemia Vera
EPO level was found to be positively associated with obesity and smoking status, making it an unreliable diagnostic factor in those patients.
Myeloproliferative Neoplasm Prophylaxis May Be Associated With Birth Rate, Maternal Outcomes
Treatment with aspirin or interferon was associated with increased odds of live birth among pregnant patients with myeloproliferative neoplasms.
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea
This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.
Low-Dose Methotrexate May Decrease Symptom Burden in Myeloproliferative Neoplasms
In a retrospective service evaluation of patients with MPNs, researchers found that low-dose methotrexate eased symptom burden of comorbidities not related to the patient’s MPN.
The Role of Vitamin K Antagonists in Managing Thrombosis in Myeloproliferative Neoplasms
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
Next post in General Hematology
